MoonLake Immunotherapeutics
MLTX
130 hedge funds and large institutions have $743M invested in MoonLake Immunotherapeutics in 2025 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 55 increasing their positions, 23 reducing their positions, and 47 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
176% more call options, than puts
Call options by funds: $37.5M | Put options by funds: $13.6M
175% more capital invested
Capital invested by funds: $270M → $743M (+$473M)
139% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 23
29.2% more ownership
Funds ownership: 59.27% → 88.47% (+29%)
0% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 47
3% less funds holding
Funds holding: 134 → 130 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$54.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$29.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$27.9M |
| 4 |
Janus Henderson Group
London,
|
+$24.6M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$14.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$7.59M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.73M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.12M |
MLTX Hedge Fund Activity: Q4 2025 in Review
130 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2025, worth a combined $743M — up 175% from $270M a quarter earlier.
Fund positioning in MLTX was balanced in Q4 2025: 47 funds opened new positions, 47 closed out, 55 added to existing stakes and 23 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $54.4M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $14.3M sold.
- 130 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2025, down from 134 in Q3 2025.
- Funds reported $743M of MoonLake Immunotherapeutics stock for Q4 2025, up 175% quarter-over-quarter.
- 47 funds opened new MoonLake Immunotherapeutics positions in Q4 2025 and 47 closed out, a net change of 0 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2025 was Deep Track Capital, an estimated $54.4M added.
- The largest MoonLake Immunotherapeutics seller in Q4 2025 was Avoro Capital Advisors, an estimated $14.3M sold.
Based on aggregated 13F filings for Q4 2025.